By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Dopaminergic antiparkinsonism agents > Carbidopa, entacapone, and levodopa > Carbidopa / Entacapone / Levodopa Dosage
Dopaminergic antiparkinsonism agents
https://themeditary.com/dosage-information/carbidopa-entacapone-levodopa-dosage-10977.html

Carbidopa / Entacapone / Levodopa Dosage

Drug Detail:Carbidopa, entacapone, and levodopa (Carbidopa, entacapone, and levodopa [ kar-bi-doe-pa, en-tak-a-pone, lee-voe-doe-pa ])

Drug Class: Dopaminergic antiparkinsonism agents

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Parkinson's Disease

Converting from Carbidopa, Levodopa, and Entacapone:

  • Switch to combination tablet that provides equivalent dose

Converting from Carbidopa and Levodopa:
  • Patients with moderate to severe dyskinesias taking levodopa doses of 600 mg or more are likely to require a reduction in levodopa dose when entacapone is added
  • Titrate patients to a dose using separate carbidopa/levodopa tablets plus entacapone, then switch to corresponding single combination tablet
  • When less levodopa is required, reduce dose by either decreasing tablet strength or extending time between doses

Concomitant Administration with Other Anti-Parkinson Drugs:
  • Dose adjustment of concomitant medications or this drug may be needed

MAXIMUM DAILY DOSE:
  • Stalevo(R) 50, 75, 100, 125 and 150: Do not exceed 8 tablets in 24-hours
  • Stalevo (R) 200: Do not exceed 6 tablets in 24-hours

Comments:
  • Conversions from carbidopa/levodopa are based on carbidopa/levodopa products combined in a 1:4 ratio; there is no experience switching patients from products that are not combined in a 1:4 ratio or from extended-release formulations.
  • Optimum dose should be determined by careful titration; therapy should be individualized and adjusted according to the desired therapeutic response.

Use: For the treatment of Parkinson's disease:
  • As a substitute for equivalent strengths of each component;
  • Or to replace carbidopa/levodopa therapy in patients experiencing signs and symptoms of end-of-dose "wearing-off" when the total daily dose of levodopa is 600 mg or less and dyskinesias are not present.

Renal Dose Adjustments

No adjustments recommended

Liver Dose Adjustments

Use with caution, especially in patients with biliary obstruction or hepatic disease

Dose Adjustments

Patients receiving less than 70 to 100 mg of carbidopa per day are more likely to experience nausea

Discontinuation or Interruption of Dosing:

  • Abrupt withdrawal or interruption in dosing is not recommended
  • Dose should be decreased slowly with careful observation

Precautions

CONTRAINDICATIONS:

  • Concomitant, or within 14 days of taking a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine
  • Narrow-angle glaucoma

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Take orally with or without food (high-fat, high-calorie meals may delay levodopa absorption by up to 2 hours)
  • Swallow whole; do not split, crush, or chew tablets
  • Only 1 tablet should be administered at each dosing interval; using multiple tablets to achieve dose is not advised

General:
  • Each combination tablet contains carbidopa-levodopa in a 1:4 ratio and entacapone 200 mg; the numerical suffix on the product name is representative of the amount of levodopa in the tablet.
  • Peripheral dopa decarboxylase is saturated by carbidopa at approximately 70 to 100 mg per day; a daily dose less than 70 to 100 mg per day may result in nausea and vomiting.

Monitoring:
  • Monitor for melanomas; ideally, periodic skin exams should be performed by appropriately qualified individuals, such as a dermatologist
  • Monitor for weight loss in patients with diarrhea
  • Monitor for drowsiness or sleepiness; ask specifically when these episodes occur
  • Monitor for development of depression with concomitant suicidal tendencies
  • Monitor for impulse control and/or compulsive behaviors; ask directed questions
  • Monitor patient closely upon therapy discontinuation or interruption
  • Periodically monitor liver function in patients on long-term therapy

Patient advice:
  • Patients should be advised to take a single tablet at each dosing interval, multiple tablets should not be taken to achieve a higher dose.
  • Patients should understand that this medication may cause a dark coloration of saliva, urine, or sweat; this coloration is clinically insignificant.
  • Patients should be advised that falling asleep during activities of daily living, including driving, have been reported. Patients should report sedating effects to their healthcare provider and speak to their healthcare provider before using alcohol or other sedating medications.
  • Patients should be advised that this drug may cause syncope, new or worsening dyskinesias, hallucinations, depression, and impulse control and/or compulsive behaviors; they should speak with their healthcare provider if these develop.
  • Patients should be advised to report nausea, vomiting, or diarrhea, especially if persistent; and myalgias, especially if associated with fever and confusion.
  • Patients should be advised not to stop taking medication abruptly.
  • Patients should notify their healthcare provider if they become pregnant or intend to become pregnant, or are breastfeeding.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by